Bortezomib-based Regimens Improve the Outcome of Patients with Primary or Secondary Plasma Cell Leukemia: A Retrospective Cohort Study.

Huijuan Wang; Huixing Zhou; Zhiyao Zhang; Chuanying Geng; Wenming Chen

Objective: The management experience for plasma cell leukemia (PCL) is still limited by PCL's rare incidence and aggressive course. The goal of this study was to further identify the efficacy of bortezomibcontaining regimens for PCL in Chinese patients. Materials and Methods: In this study, 56 consecutive PCL patients [14 primary PCL (pPCL) and 42 secondary PCL (sPCL) cases] were retrospectively enrolled and 42/56 patients received bortezomibbased regimens (BBRs), including 10/14 pPCL and 32/42 sPCL patients. The patients' survival data, clinical information, and safety data were collected and analyzed. Results: In pPCL and sPCL patients, the overall response rate in the bortezomib group was 90.0% and 25.0%, respectively. The median progression-free survival from PCL diagnosis for pPCL and sPCL was 8.3 months vs. 2.9 months (p=0.043) and median overall survival (OS) from PCL diagnosis was 23.3 months vs. 4.0 months. The OS for patients receiving BBRs was significantly longer for both pPCL (8.3 vs. 1.2 months, p=0.002) and sPCL (4.3 vs. 1.1 months, p<0.001). In multivariate COX analysis, BBR treatment [p=0.008, hazard ratio (HR)=0.38, 95% confidence interval (CI)=0.19-0.77] and very good partial response or better (≥VGPR) (p=0.035, HR=0.19, 95% CI=0.04- 0.74) were independent predictors of OS for sPCL patients. For pPCL patients, BBR predicted OS (p=0.029, HR=0.056, 95% CI=0.004-0.745) instead of ≥VGPR (p=0.272, HR=3.365, 95% CI=0.38-29.303). Conclusion: It was found that BBRs could significantly improve OS for both pPCL and sPCL patients.

CONFIDENCE intervals; LEUKEMIA; MULTIVARIATE analysis; PLASMACYTOMA; SURVIVAL; RETROSPECTIVE studies; DESCRIPTIVE statistics; BORTEZOMIB

Turkish Journal of Hematology, 2020, Vol 37, Issue 2, p91

1300-7777

Academic Journal

10.4274/tjh.galenos.2019.2019.0254